Zhejiang Shapuaisi Pharmaceutical Co Ltd (603168) - Total Assets
Based on the latest financial reports, Zhejiang Shapuaisi Pharmaceutical Co Ltd (603168) holds total assets worth CN¥2.13 Billion CNY (≈ $311.96 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Zhejiang Shapuaisi Pharmaceutical Co Ltd cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Zhejiang Shapuaisi Pharmaceutical Co Ltd - Total Assets Trend (2008–2024)
This chart illustrates how Zhejiang Shapuaisi Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Check 603168 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Zhejiang Shapuaisi Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Zhejiang Shapuaisi Pharmaceutical Co Ltd's total assets of CN¥2.13 Billion consist of 17.4% current assets and 82.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 3.9% |
| Accounts Receivable | CN¥80.62 Million | 3.8% |
| Inventory | CN¥76.66 Million | 3.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥215.83 Million | 10.3% |
| Goodwill | CN¥332.09 Million | 15.8% |
Asset Composition Trend (2008–2024)
This chart illustrates how Zhejiang Shapuaisi Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 603168 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Shapuaisi Pharmaceutical Co Ltd's current assets represent 17.4% of total assets in 2024, a decrease from 50.4% in 2008.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2024, down from 4.4% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 25.0% of total assets, an increase from 4.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 15.8% of total assets.
Zhejiang Shapuaisi Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Zhejiang Shapuaisi Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Eris Lifesciences Limited
NSE:ERIS
|
India | Rs71.60 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Lotus Pharmaceutical Co Ltd
TW:1795
|
Taiwan | NT$106.15 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC
|
India | Rs3.22 Billion |
Zhejiang Shapuaisi Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.16 | 1.31 | 1.79 |
| Quick Ratio | 0.83 | 1.04 | 1.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥56.85 Million | CN¥95.49 Million | CN¥285.73 Million |
Zhejiang Shapuaisi Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhejiang Shapuaisi Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.71 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -3.0% |
| Total Assets | CN¥2.11 Billion |
| Market Capitalization | $278.66 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Shapuaisi Pharmaceutical Co Ltd's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Zhejiang Shapuaisi Pharmaceutical Co Ltd's assets decreased by 3.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Zhejiang Shapuaisi Pharmaceutical Co Ltd (2008–2024)
The table below shows the annual total assets of Zhejiang Shapuaisi Pharmaceutical Co Ltd from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.11 Billion ≈ $308.21 Million |
-2.95% |
| 2023-12-31 | CN¥2.17 Billion ≈ $317.58 Million |
+10.86% |
| 2022-12-31 | CN¥1.96 Billion ≈ $286.47 Million |
+23.49% |
| 2021-12-31 | CN¥1.59 Billion ≈ $231.99 Million |
-5.23% |
| 2020-12-31 | CN¥1.67 Billion ≈ $244.80 Million |
+5.26% |
| 2019-12-31 | CN¥1.59 Billion ≈ $232.57 Million |
-3.60% |
| 2018-12-31 | CN¥1.65 Billion ≈ $241.24 Million |
-11.81% |
| 2017-12-31 | CN¥1.87 Billion ≈ $273.55 Million |
+1.48% |
| 2016-12-31 | CN¥1.84 Billion ≈ $269.56 Million |
+44.48% |
| 2015-12-31 | CN¥1.27 Billion ≈ $186.57 Million |
+46.16% |
| 2014-12-31 | CN¥872.34 Million ≈ $127.65 Million |
+45.98% |
| 2013-12-31 | CN¥597.57 Million ≈ $87.44 Million |
+15.69% |
| 2012-12-31 | CN¥516.54 Million ≈ $75.59 Million |
+57.78% |
| 2011-12-31 | CN¥327.38 Million ≈ $47.91 Million |
+47.15% |
| 2010-12-31 | CN¥222.49 Million ≈ $32.56 Million |
+19.09% |
| 2009-12-31 | CN¥186.82 Million ≈ $27.34 Million |
+14.74% |
| 2008-12-31 | CN¥162.82 Million ≈ $23.83 Million |
-- |
About Zhejiang Shapuaisi Pharmaceutical Co Ltd
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company provides its products to ophthalmology, antimicrobials, gynecology, and other classes. It offers its products in injections, oral solutions, eye drops, large-volume injections, oral solutions, tablets, granules, and other dosage forms. Zhejiang Shapuaisi… Read more